The Usnic Acid Analogue 4‑FPBUA Enhances the Blood–Brain Barrier Function and Induces Autophagy in Alzheimer’s Disease Mouse Models

• Published in: ACS chemical neuroscience 2024-09, Vol.15 (17), p.3152-3167
• Main Authors: Al Rihani, Sweilem B., Elfakhri, Khaled H., Ebrahim, Hassan Y., Al-Ghraiybah, Nour F., Alkhalifa, Amer E., El Sayed, Khalid A., Kaddoumi, Amal
• Format: Article
• Language: English
• Subjects: Alzheimer Disease - drug therapy; Alzheimer Disease - metabolism; Amyloid beta-Peptides - metabolism; Animals; Autophagy - drug effects; Autophagy - physiology; Benzofurans - pharmacology; Blood-Brain Barrier - drug effects; Blood-Brain Barrier - metabolism; Disease Models, Animal; Humans; Mice; Mice, Transgenic
• ISSN: 1948-7193; 1948-7193
• DOI: 10.1021/acschemneuro.4c00326

Preclinical and clinical studies have indicated that compromised blood–brain barrier (BBB) function contributes to Alzheimer’s disease (AD) pathology. BBB breakdown ranged from mild disruption of tight junctions (TJs) with increased BBB permeability to chronic integrity loss, affecting transport across the BBB, reducing brain perfusion, and triggering inflammatory responses. We recently developed a high-throughput screening (HTS) assay to identify hit compounds that enhance the function of a cell-based BBB model. The HTS screen identified (S,E)-2-acetyl-6-[3-(4′-fluorobiphenyl-4-yl)­acryloyl]-3,7,9-trihydroxy-8,9b-dimethyldibenzo-[b,d]­furan-1­(9bH)-one (4-FPBUA), a semisynthetic analogue of naturally occurring usnic acid, which protected the in vitro model against Aβ toxicity. Usnic acid is a lichen-derived secondary metabolite with a unique dibenzofuran skeleton that is commonly found in lichenized fungi of the genera Usnea. In this study, we aimed to evaluate the effect of 4-FPBUA in vitro on the cell-based BBB model function and its in vivo ability to rectify BBB function and reduce brain Aβ in two AD mouse models, namely, 5xFAD and TgSwDI. Our findings demonstrated that 4-FPBUA enhanced cell-based BBB function, increased Aβ transport across the monolayer, and reversed BBB breakdown in vivo by enhancing autophagy as an mTOR inhibitor. Induced autophagy was associated with a significant reduction in Aβ accumulation and related pathologies and improved memory function. These results underscore the potential of 4-FPBUA as a candidate for further preclinical exploration to better understand its mechanisms of action and to optimize dosing strategies. Continued research may also elucidate additional pathways through which 4-FPBUA contributed to the amelioration of BBB dysfunction in AD. Collectively, our findings supported the development of 4-FPBUA as a therapeutic agent against AD.